The C3i Accell program provides up to 12 months of technical development and business support, leveraging the learnings from the core C3i Program to advance the translation of biomedical technologies. Investigators with active NIH-funded research projects, who have recently completed the core C3i Program, may receive administrative supplement funding to address both technical and commercialization risks identified through their entrepreneurial training experience. The Project Teams will continue to receive mentored support from their C3i Business Advisors and Project Managers through frequent teleconferences.
The primary objective of C3i Accell is to complete proof-of-concept studies and facilitate preparations for commercialization through start-up formation, strategic partnership, or out-licensing. It is expected that Project Teams forming start-up companies will be well-positioned to compete for NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants to further commercial development efforts.
The C3i Accell program is being offered to investigators who have active NIH-funded research projects from participating Institutes and Centers and who have recently completed the core C3i Program. Applicants may request up to $100,000 in direct costs for up to 12 months. Up to 4 project teams will be selected to participate in the C3i Accell program in 2022.
The following Institutes and Centers will be participating in the 2022 C3i Accell program. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about this program before submitting an application.
Ilana G. Goldberg
The C3i Accell program is being offered to investigators who have active NIH-funded research projects from participating Institutes and Centers and who have recently completed the core C3i Program. Eligible investigators may submit administrative supplement requests to advance technology development and translational research aims consistent with the peer-reviewed objectives of the parent grant. Investigators may propose research and development efforts that incorporate the learnings from the C3i Program and take advantage of unanticipated opportunities to increase the value of the project.
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) will support active grant awards from research project (R01, U01, P41) activity codes.
Application Due Date: July 11, 2022
Notice of Participation: August 11, 2022
Program Start Date: October 11, 2022
Program End Date: October 20, 2023
How to Apply
To be considered for participation in the 2022 C3i Accell program, administrative supplement requests should be submitted to PA-20-272, Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional). The requested supplemental budget cannot exceed $100,000 in direct costs for up to 12 months. The project and budget periods of the supplement request must be within the currently approved project period for the existing parent award. Administrative supplements must add value to the science proposed in the aims of the original project, as such they must be within the scientific scope of the parent grant.
These administrative supplements are available to meet increased costs that are within the scope of the approved award but were unforeseen when the application was submitted. Applicants are strongly encouraged to discuss the aims of the proposed work with the NIBIB program officer assigned to the parent grant to assess suitability for this funding opportunity.